These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 37791037

  • 1. A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
    Zhang Z, Shi M, Li Z, Ling Y, Zhai L, Yuan Y, Ma H, Hao L, Li Z, Zhang Z, Hölscher C.
    Parkinsons Dis; 2023; 2023():7427136. PubMed ID: 37791037
    [Abstract] [Full Text] [Related]

  • 2. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
    Lv M, Xue G, Cheng H, Meng P, Lian X, Hölscher C, Li D.
    Brain Behav; 2021 Aug; 11(8):e2231. PubMed ID: 34125470
    [Abstract] [Full Text] [Related]

  • 3. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Aug; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

  • 4. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, Hölscher C.
    Eur J Pharmacol; 2017 Oct 05; 812():82-90. PubMed ID: 28666800
    [Abstract] [Full Text] [Related]

  • 5. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
    Zhang L, Li C, Zhang Z, Zhang Z, Jin QQ, Li L, Hölscher C.
    Parkinsons Dis; 2022 Oct 05; 2022():1428817. PubMed ID: 36419409
    [Abstract] [Full Text] [Related]

  • 6. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
    Su Y, Liu N, Zhang Z, Li H, Ma J, Yuan Y, Shi M, Liu J, Zhao Z, Zhang Z, Holscher C.
    Eur J Pharmacol; 2022 Jul 05; 926():175029. PubMed ID: 35584709
    [Abstract] [Full Text] [Related]

  • 7. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
    Zhang L, Zhang L, Li L, Hölscher C.
    J Parkinsons Dis; 2019 Jul 05; 9(1):157-171. PubMed ID: 30741689
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
    Zhang L, Zhang L, Li L, Hölscher C.
    Neuropeptides; 2018 Oct 05; 71():70-80. PubMed ID: 30017231
    [Abstract] [Full Text] [Related]

  • 9. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ, Hölscher C.
    Peptides; 2020 Mar 05; 125():170184. PubMed ID: 31705913
    [Abstract] [Full Text] [Related]

  • 10. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
    Zhang Z, Hao L, Shi M, Yu Z, Shao S, Yuan Y, Zhang Z, Hölscher C.
    J Parkinsons Dis; 2021 Mar 05; 11(2):529-543. PubMed ID: 33523018
    [Abstract] [Full Text] [Related]

  • 11. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C.
    Neuropharmacology; 2018 May 01; 133():385-394. PubMed ID: 29462693
    [Abstract] [Full Text] [Related]

  • 12. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L, Li D, Feng P, Li L, Xue GF, Li G, Hölscher C.
    Neuroreport; 2016 Apr 13; 27(6):384-91. PubMed ID: 26918675
    [Abstract] [Full Text] [Related]

  • 13. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, Hölscher C.
    Brain Res; 2016 Mar 01; 1634():1-11. PubMed ID: 26453833
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C.
    Expert Opin Ther Targets; 2022 May 01; 26(5):445-460. PubMed ID: 35584372
    [Abstract] [Full Text] [Related]

  • 15. Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
    Panagaki T, Randi EB, Szabo C, Hölscher C.
    J Parkinsons Dis; 2023 May 01; 13(7):1149-1174. PubMed ID: 37718851
    [Abstract] [Full Text] [Related]

  • 16. Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
    Lin TK, Lin KJ, Lin HY, Lin KL, Lan MY, Wang PW, Wang TJ, Wang FS, Tsai PC, Liou CW, Chuang JH.
    Front Mol Neurosci; 2021 May 01; 14():697440. PubMed ID: 34305527
    [Abstract] [Full Text] [Related]

  • 17. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
    Jalewa J, Sharma MK, Hölscher C.
    J Neurochem; 2016 Oct 01; 139(1):55-67. PubMed ID: 27412483
    [Abstract] [Full Text] [Related]

  • 18. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO.
    Neuropharmacology; 2020 Jan 01; 162():107813. PubMed ID: 31628935
    [Abstract] [Full Text] [Related]

  • 19. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
    Cao Y, Hölscher C, Hu MM, Wang T, Zhao F, Bai Y, Zhang J, Wu MN, Qi JS.
    Eur J Pharmacol; 2018 May 15; 827():215-226. PubMed ID: 29551659
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model.
    Zhang LY, Jin QQ, Hölscher C, Li L.
    Neural Regen Res; 2021 Aug 15; 16(8):1660-1670. PubMed ID: 33433498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.